A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab
Clinical trial NCT07268521 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07268521
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-01
- Primary completion
- 2028-04-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.